(Raine) Study, a large, richly phenotyped pregnancy cohort, commenced in 1989; by 2008, the Study had grown to include a wide range of disciplines, and had 73 publications. To capitalise on this success, and secure the Study's long-term competitiveness, a management structure and governance procedures were developed to foster research excellence.
Background: Shared decision-making models of prenatal care with decision aid tools may increase trial of labour after cesarean (TOLAC) rates. We hypothesised that women receiving a comprehensive decision aid within a shared decision-making model of care would have higher uptake of TOLAC compared with standard shared decision-making model of care only.
Methods: This was a comparative effectiveness randomised controlled trial in the Positive Birth After Caesarean Clinic in a tertiary urban hospital. Participants were 297 women with one previous caesarean and singleton pregnancy less than 25 weeks gestation. Primary outcome was TOLAC.
Results: TOLAC rates for women receiving standard care were similar to women receiving the additional decision aid (60.8% vs 56.9%). Women initially unsure of birth preference assigned decision aid were more likely to prefer TOLAC (49% vs 33%). No differences seen in knowledge, decisional conflict, birth satisfaction, or adherence to choice. The decision aid was rated highest for helping women organize their thoughts, consider pros/cons, identify questions, and know what to expect.
Conclusions: A decision aid could slightly improve outcomes in the context of a 'real-world' shared decision-making model of care in a setting with high TOLAC rate. It may be most useful for women seen in general prenatal care models where time limitations do not afford comprehensive counselling and support, or for women who are initially unsure of their birth preference. Stillbirth has long-lasting psychosocial impacts for families and health services, one focus of impact is a subsequent pregnancy. The majority of parents will conceive again following stillbirth, and in these pregnancies parents face an increased risk of stillbirth and other adverse outcomes, and many experience profound anxiety and stress. Despite the need, there is currently little evidence to guide clinical practice.
CARE PRIOR TO AND DURING SUBSEQUENT PREGNANCIES FOLLOWING STILLBIRTH FOR
Methods: A Cochrane systematic review of RCTs was conducted to assess the effects of different interventions or models of care prior to and during subsequent pregnancies following stillbirth on maternal, fetal, neonatal and family health outcomes, and health service utilisation. Parents with a history of stillbirth of 20 weeks gestation or more, who are pregnant or considering a subsequent pregnancy, were included.
Results: Nine trials were identified, assessing the use of (or combinations of the use of) lose-dose aspirin, low molecular weight heparin, intravenous immunoglobulin, third-party leukocyte immunisation, and progesterone therapy. The trials randomised 34 to 449 women, of which 6 to 45 were eligible for inclusion in our review. We found no differences among the primary outcomes (stillbirth; neonatal death; adverse perinatal outcome; adverse maternal psychological effects) across the interventions, though the number of studies and number of women included in each comparison was small.
Conclusions: Based on these findings, there is insufficient evidence to guide clinical practice for care in pregnancies following stillbirth. Large-scale RCTs are needed to assess the effectiveness of specific interventions for reducing the risk of stillbirth recurrence and improving other outcomes. Results: There were 90 infants in Epoch 1 and 84 infants in Epoch 2. Median birthweight was 1017 gms vs 1122 gms (p= 0.12). Median gestational age was 27 weeks vs 28 weeks (p=0.032). There was a significant reduction in number of infants requiring ventilation by age 72 hours 21.1% vs 7.1% (p=0.017). There was a significant increase in number of infants treated with surfactant 20% vs 34.5% (p=0.014). The median age of first surfactant therapy reduced from 12 hrs to 3 hrs (p=0.008). There was a trend to reduction in mortality but this was not significant 10% vs 2.4% (p=0.23). There was a non-significant reduction in chronic lung disease (CLD) 34.4% vs 26.2% (p=0.3) and CLD/Death 42.2% vs 28.6% (p=0.23). Other morbidities were unchanged.
IMPACT OF THE INTRODUCTION OF MINIMALLY
Conclusions: Introduction of MIST in preterm infants at 25 to
